Immunotherapy for head and neck cancers by Aremu, Shuaib K. et al.
 
                                                                                              
                                                                                                   International Surgery Journal | October 2019 | Vol 6 | Issue 10    Page 3884 
International Surgery Journal 
Aremu SK et al. Int Surg J. 2019 Oct;6(10):3884-3888 
http://www.ijsurgery.com pISSN 2349-3305 | eISSN 2349-2902 
Review Article 
Immunotherapy for head and neck cancers 
Shuaib K. Aremu
1




















Head and neck squamous cell carcinoma (HNSCC) is a 
frequent tumour which arises from various anatomical 
areas in the head and neck region. It accounts for more 
than 550,000 new cases and 380,000 deaths annually.1,2 
Radiotherapy or surgery is the general single modality 
early-stage treatment for the condition. For the tumours 
that have advanced, the treatment is multimodal. 
Palliative chemotherapy is the standard of care for 
metastatic HNSCC. There is limited prognosis and an 
urgent need for novel treatment approaches. HNSCC has 
multiple resistance mechanisms through which it evades 
the immune responses. It is particularly characterized by 
an immunosuppressive environment which includes the 
release of immunosuppressive factors, expansion, and 
expansion of immune cells which have inhibitory activity 
reduction of tumour immunogenicity. Proper clinical 
trials and rational design of immunotherapeutic 
approaches have resulted from an in-depth understanding 
of these mechanisms. Presently, only inhibitors of 
immune checkpoints have proven clinical efficacy in 
randomized phase III trials, PD-1 (programmed cell death 
1) and PD-L1 (programmed cell death 1 ligand).3,4 The 
only drug approved for platinum-refractory metastatic 
HNSCC is the PD-1 inhibitor nivolumab. Even so, a 
variety of other immunotherapeutic treatment options are 
being investigated. There are ongoing trails which 
investigate the immunotherapeutic approaches in the 
curative setting and therapy combination using a variety 
of immunotherapeutic approaches. This article provides a 
comprehensive overview of the development of 
immunotherapeutic approaches and the role of the 
immune system in the progression and development of 
HNSCC. It particularly focuses on the currently approved 
immunotherapy and the promising immunotherapeutic 
approaches under clinical investigation.  
ABSTRACT 
 
Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour which arises from various anatomical areas 
in the head and neck region. HNSCC has multiple resistance mechanisms through which it evades the immune 
responses. It is particularly characterized by an immunosuppressive environment which includes the release of 
immunosuppressive factors, expansion, and expansion of immune cells which have inhibitory activity reduction of 
tumour immunogenicity. Human papillomavirus positive (HPV+) HNSCC tumours have one of the higher levels of T 
cells infiltration. Studies which explore this relationship to the prognosis of patients vary, with some showing benefit 
only with high CD8/Treg ratio as seen with HPV+ disease and others showing improved prognosis with a higher 
number of TIL Treg. High CD8+ TIL seen in HPV + disease has been shown in several studies to confer improved 
disease-free survival. The most successful vaccination strategy is preventive vaccination for HPV. Investigations 
using different approaches have been carried out on therapeutic vaccines for HPV-associated HNSCC. Despite 
immune responses being seen in a number of studies, these vaccines are still not effective for clinical use as of yet.  
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IMMUNOLOGY OF CANCER 
The immune system ideally recognized tumor cells in a 
premalignant state and destroys these cells. However, 
tumor cells are able to develop mechanisms to thwart 
immune response and recognition – a process called 
immunoediting, which leads to immune escape.5 IR 
(inhibitory checkpoint receptors) expressed on activated 
immune cells Monocyte-derived dendritic cells from 16 
patients were loaded with two modified HLA-class I p53 
peptides and were injected into inguinal lymph nodes. 
The frequencies of p53-specific T cells were increased in 
11 of 16 patients (69%), with interferon-γ secretion 
detected in 4 of 16 patients. Moreover, the rate of Tregs 
was decreased after vaccination.6 The expression of these 
inhibitory receptors often signifies an exhausted T cell, 
which has lost its normal function, which includes 
reduced cytolytic activity. This state of dysfunction can, 
however, be reversed by IR blockade. Resistance 
mechanisms to this T cell reinvigoration process may 
arise from expression of multiple IR or other acquired 
cellular changes.  
IMMUNOLOGY OF HNSCC 
The modifications in immune systems in HNSCC 
patients show that cancer is an overall 
immunosuppressive process. HNSCC patients, in the 
peripheral bloodstream, have a lower number of white 
blood cells, which is comprised of a greater proportion of 
suppressive regulatory T cells. Within the HNSCC 
tumours there are even more suppressive population of 
Treg cells than in the peripheral bloodstream of HNSCC 
patients.7  
Human papillomavirus positive (HPV+) HNSCC tumours 
have one of the higher levels of T cells infiltration. 
Studies which explore this relationship to the prognosis 
of patients vary, with some showing benefit only with 
high CD8/Treg ratio as seen with HPV+ disease and 
others showing improved prognosis with a higher number 
of TIL Treg.8,9 High CD8+ TIL seen in HPV + disease 
has been shown in several studies to confer improved 
disease-free survival.9,10 These cell populations express 
IR that can be targeted by inhibitory checkpoint receptor 
blockade therapy (ICR). 
VACCINES 
Basically, the principles of therapeutic cancer vaccines 
can be summarized as follows. 
 Peptide-based vaccines which are produced through 
the combination of one of more proteins or peptides 
which is commonly expressed in the specific tumour 
with an adjuvant. The immune system, in response to 
the adjuvant, will also respond to the tumour cells 
which express the respective antigens.  
 DNA/RNA-based vaccines use nucleic acids which 
have been exogenously manipulated so that when 
injected, expresses a tumour specific antigen. The 
antigen-presenting cells process this antigen and 
induce a specific immune response toward tumour 
specific cells which express the same antigen.  
 Viral vectors and attenuated bacteria can serve as 
vectors for delivering plasmids encoding genes or 
proteins of interest in vaccines.11,12  
 For dendritic cell vaccines, an isolation of the 
dendritic cells from the blood of cancer cells is done 
through leucapheresis and stimulated with a tumour 
antigen. The cells are re-injected and serve to 
activate the T-cells, which are specific to the tumour.  
 Peptide/protein-based vaccines 
The incidence of HPV-associated oropharyngeal 
carcinoma has increased rapidly during the last decades 
in developed countries worldwide, although the incidence 
of smoking- alcohol-induced HNSCC is declining 
steadily.13 HPV16 caused approximately 90 percent of 
these cases, and the remainder is caused by other 
oncogenic HPV types.13,14 By 2020, it is estimated that 
the annual number of cervical cancers diagnosed in the 
U.S. will be surpassed by the number of HPV-positive 
HNSCCs.13 Randomized prophylactic HPV vaccine trials 
have shown effectiveness in preventing high-grade 
cervical lesions associated with HPV18 and HPV16.15 
Therefore the current recommendation for preventing 
genital warts, anal, vulva, vaginal and cervical 
precancerous lesions worldwide is prophylactic HPV 
vaccination with quadrivalent (HPV16/18/8/11) or 
bivalent (HPV16/18) vaccines, including Switzerland.16  
Additional randomized trials have showed that the 
vaccines are associated with significantly reduced HPV-
associated anogenital lesions in males.17 As a result, the 
prophylactic vaccination has been approved for boys and 
young males. A recent cross-sectional study showed that 
HPV vaccination reduced the prevalence of oral 
HPV16/18/6/11 infections significantly.18 While the 
effectiveness of prophylactic HPV vaccination is high, its 
administration and general adoption is poor.  
HPV-associated cancers strongly and consistently 
overexpress the cyclin-dependent kinase inhibitor 
p16(INK4a). A study published recently investigated a 
p16(INK4a)-based peptide vaccine in patients who had 
advanced HPV-positive HNSCC.19 The participants were 
20 patients who received at least four injections, and their 
immune response was evaluate. In 14 of the 20, CD4+ T 
cells were detected, and in 5 patients CD5+ cells were 
detected, and antibodies in 14 of 20 patients. Vaccination 
was safe with low toxicity rates. Tumour response could 
be assessed in 14 patients. Of these, nine patients (64%) 
had a stable disease as their best overall response. In the 
VICORYX-2 trial, this vaccination is being investigated 
in combination with cisplatin-based chemotherapy in 
patients with advanced HPV-positive cervical, vulvar, 
vaginal, penile, anal or head and neck cancer 
(NCT02526316).20 
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Another study had utilized an immunomodulatory peptide 
vaccine for melanoma antigen, and HPV-positive A3-
positive tumours elicited antibody responses and antigen-
specific T cells to the respective vaccines but did not 
have clinical efficacy.21 In a different phase, I/II study, 
the safety profile of Allovax is being investigated in 
patients with recurrent HNSCC.22 AlloVax is a vaccine 
made up of patient-specific tumour antigen derived from 
chaperone-rich tumour cell lysate. Personalized 
neoantigen vaccines have recently been developed and 
investigated. The basis of this approach is parallel 
sequencing so that all coding mutations within tumours 
are detected, and machine learning approaches utilized to 
predict which of the mutated peptides have high affinity 
binding of autologous human leukocyte antigen (HLA) 
molecules.  
DNA/RNA-based vaccines 
There have been multiple attempts to use therapeutic 
HPV vaccines. A DNA-based cancer vaccine MEDI0457 
(previously called INO-3112) has two main components: 
INO-9012 which is a DNA plasmid which contains 
immune activator interleukin-12 and VGX-3100 which is 
a DNA plasmid with modified sequences for E7 and E6. 
A phase I/II trial’s preliminary results showed that this 
DNA based immunotherapy could generate HPV-specific 
CD8 T cell immunity safely in patients who have locally 
advanced HPV-related HNSSC.23 All the patients who 
had been tested showed positive cellular immune 
responses in at least one assay. The ongoing phase I/II 
study of MEDI0457 is combining the anti-PD-L1 
antibody durvalumb in patients with HPV-positive 
recurrent HNSCC.  
A recent phase II trial which utilized a multipeptide 
vaccine for three cancer-testis-antigens (IMP3, LY6K, 
and CDCA1) showed a significant benefit of survival 
when compared to the untreated cohort in metastatic 
HNSCC.24  
Attenuated bacterial and viral vectors 
ADXS11-001 is a live attenuated Listeria monocytogenes 
(Lm)-listeriolysin O (LLO) immunotherapy which is 
biologically engineered to produce a secretion of an 
HPV-E7 tumour antigen as a truncated LLO-E7 fusion 
protein in cells which are capable of presenting antigen. 
A study which is still ongoing includes HPV-positive 
oropharyngeal prior to surgery. The ongoing phase I/II 
trial is investigating the combination of ADXS11-001 
with durvalumab and the efficacy of durvalumab 
compared alone. DPX-E7 is an HPV16-E711-19 nanomer 
vaccine currently investigated in HPV-positive cancers.  
Dendritic cell vaccines 
There has also been the investigation of HPV-targeting 
dendritic cell vaccines against cervical cancer. While the 
measure of HPV-specific cytotoxic T lymphocytes was 
possible, there was no observable clinical response.25 The 
activity of dendritic cell vaccines, in preclinical trials, 
have been improved through a recombinant adenovirus 
expressing codon-optimized HPV E6/E7 fusion proteins. 
A test was carried out of a dendritic cell-based 
vaccination against p53 in a phase I trial in patients with 
resected HNSCC.26 Monocyte-derived dendritic cells 
from 16 patients were loaded with two modified HLA-
class I p53 peptides and were injected into inguinal 
lymph nodes. The frequencies of p53-specific T cells 
were increased in 11 of 16 patients (69%), with 
interferon-γ secretion detected in 4 of 16 patients. 
Moreover, the rate of Tregs was decreased after 
vaccination. 
THE FUTURE OF IMMUNO-ONCOLOGY 
The future of immunotherapy holds an exciting promise. 
There are trials underway for evaluating immunotherapy 
combine with the existing cytotoxic agents at varying 
dose regiments. Currently, the goals of immunotherapy 
clinical trials include developing appropriate regimen 
with the least toxicity with durable responses. The best 
chance for curative therapy is targeting the redundant 
pathway mechanisms which lead to the progression of 
cancer. Significant barriers to progress are the patients 
with tumours that have poor lymphocyte infiltration. 
COMBINING IMMUNOTHERAPY AGENTS  
In spite of the enthusiasm towards ICR, most patients do 
not benefit from anti-PDI therapy. As such interest has 
turned to the combination of ICR agents with the hope to 
overcome multiple resistance layers to increase efficacy 
in a synergistic manner, at the same time maintaining an 
acceptable toxicity profile. It is unclear how the blockade 
of one immune checkpoint receptor affects other 
checkpoint receptors, and whether that blockade leads to 
cross talk with other pathways or downstream. There is a 
profound synergy shown by the use of combination 
immunotherapies and a likelihood of further advances in 
treatment compared to the current cytotoxic regimens or 
monotherapy. 
There are emerging trials which are trying to evaluate the 
targeting of checkpoint receptors other than PDI. 
Preclinical studies have shown numerous promising 
potential therapeutic targets, and there is an ongoing test 
of these agents in combination with other anti-PDI 
therapy. PDI and CTLA4 are considered pathways that 
are non-redundant. The test on melanoma patients 
confirms the synergism of blockade of these two IRs.27 
Trials are underway evaluating this combination in other 
solid tumors. Other combinations are being tested in 
HNSCC.  
IMMUNOTHERAPY AND RADIATION 
Radiation therapy has historically been considered an 
immunosuppressive treatment modality with the 
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mechanism of cell death related to direct DNA damage.28, 
29 In vitro studies, RT triggers ICD (immunogenic cell 
death), a process which converts the tumour which has 
been irradiated into a situ vaccine.30 There are proposed 
theories which show the potential advantage that can be 
achieved through radiation with immunotherapy, one of 
which pushes that ICD has the potential of enhancing 
systemic responses via an ‘abscopal effect’. Here, local 
therapy induces a systemic response capable of lasting 
beyond the RT treatment completion.31 Such changes 
have the ability of altering the TME to make it more 
responsive to PDI pathway blocking agents. Preclinical 
abscopal responses demonstrate the additive effects the 
RT has when combined with anti-PDI therapy.  
CONCLUSION 
As it stands presently, the most successful vaccination 
strategy is preventive vaccination for HPV. Investigations 
using different approaches have been carried out on 
therapeutic vaccines for HPV-associated HNSCC. 
Despite immune responses being seen in a number of 
studies, these vaccines are still not effective for clinical 
use as of yet. It is noteworthy however, that combined 
with other immunotherapeutic strategies, namely immune 
checkpoint inhibitors might be promising. The future of 
immunotherapy holds an exciting promise. There are 
trials underway for evaluating immunotherapy combine 
with the existing cytotoxic agents at varying dose 
regiments. Currently, the goals of immunotherapy clinical 
trials include developing appropriate regimen with the 
least toxicity with durable responses. The best chance for 
curative therapy is targeting the redundant pathway 
mechanisms which lead to the progression of cancer. 
Significant barriers to progress are the patients with 
tumours that have poor lymphocyte infiltration.  
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